"I love Kite Pharma, Changing the Way Cancer is Treated"

2022-05-07 04:09:56

Sorry, your browser does not support JavaScript! For the latest updates on Gilead’s ongoing response to COVID-19, please click here. × Find a Treatment Center Investor Relations Contact Us KiteKonnect® About Us Our Mission Our Story Therapeutic Areas Leadership Kite Locations Science & Medicine Our Technology Our Therapies Pipeline Trials & Expanded Access External Research Program (ERP) Newsroom Newsroom Press Releases Company Statements Media Kit Careers Now Hiring Careers at Kite Manufacturing Careers at Kite Early Talent Programs at Kite Culture & Benefits Utility Contact Us KiteKonnect® BACK TO MAIN MENU Company Statements Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma Kite Announces U.S. FDA Clearance of Investigational Find a Treatment Center Investor Relations Toggle Inner Dropdown BACK TO MAIN MENU Google.com Focused on the Cure Kite is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. See Our Mission Our science Our goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy — using genetically modified immune cells to target tumors.Our engineered cell therapies express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. This dual platform has the potential to transform cancer treatment by addressing the goal of treating both hematological cancers and solid tumors. Learn More Shon, blood cancer survivor, and his wife, Lisa Our Pipeline Our industry-leading cell therapy pipeline is charging ahead to address the unmet need in hematologic cancers, potentially bringing the benefits of cell therapy to patients with solid tumors and advancing the next generation of treatment, such as allogeneic therapies. See Our Pipeline Our Therapies Kite has been at the forefront of cancer immunotherapy since 2009. Today, we are a leader in engineered T cell therapy, which has changed the paradigm of cancer treatment as one of the biggest breakthroughs in medicine since the introduction of combination chemotherapy more than 60 years ago. We are driven by our mission to bring these potentially lifesaving therapies to the patients who need them most. Discover Our Therapies Our Authorized Treatment Centers Kite is proud to have more than 250 authorized treatment centers (ATCs) where patients can receive CAR T-cell therapy across the globe, including more than 110 in the U.S.ATCs are independent facilities certified to dispense Kite CART therapies. Choice of an ATC is within the sole discretion of the physician and patient. Kite does not endorse any individual treatment sites. Our Treatment Centers Change the Future of Cancer Treatment with Us Are you passionate about changing the way cancer is treated? Let’s talk. Explore Open Positions A Letter from Christi Shaw, CEO Christi shares her vision for Kite as we continue pushing the boundaries of science to help patients in need. Read Here AREAS OF INTEREST Our Mission Our Technology Pipeline Careers at Kite INFORMATION Contact Us Newsroom Investors KiteKonnect.com Gilead.com Sitemap LEGAL Privacy Policy Terms and Conditions Compliance Program Social Media Guidelines FOLLOW US © 2017-2022 Gilead Sciences, Inc. All rights reserved. For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483)